Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd., planning to invest in a 24% stake in Jikun Pharmaceutical, securing rights to an innovative drug for treating pulmonary fibrosis and gaining priority purchase rights for all global compound rights of Jikun's products [1][2]. Group 1 - The strategic investment will allow Baiyang Pharmaceutical to lock in all rights related to the innovative drug project JK1033, which targets idiopathic pulmonary fibrosis (IPF) through a novel mechanism [1]. - JK1033 is a small molecule compound that can inhibit multiple fibrosis-related target cells/pathways, achieving anti-fibrotic, anti-inflammatory, and anti-epithelial injury effects [1]. - The project has initiated Phase I clinical trials in China and has completed Pre-IND communication with the FDA in the United States, with plans to submit an IND application [1]. Group 2 - Upon achieving certain progress in the JK1033 project, Baiyang Pharmaceutical will have the right to acquire the project rights at a mutually agreed reasonable price, which will enhance its product pipeline in the innovative drug sector [2]. - This collaboration will strengthen Baiyang's product portfolio in the treatment of liver and pulmonary fibrosis, consolidating its position in the fibrosis disease treatment field [2].
24%入股 抗肺纤维化创新疗法JK1033被医药头部企业锁定